Partner, Medicxi | Former Scientific head of Operation Warp Speed (Until January 2021)
Moncef is a Partner at Medicxi and has been with the firm since September 2017. He is currently dedicating his attention and focus as Chief Scientist for Operation Warp Speed – the fast track programme for the development of a COVID-19 vaccine and therapeutic in the US.
Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division. From this leadership role, Moncef spearheaded a profound overhaul of GSK’s pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units. During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.